Anew Labs raises $290m at $1.5bn valuation for AI drug discovery

ByteDance's AI drug discovery spin-off Anew Labs has closed a reported $290m first external round, led by HSG, IDG Capital and Hillhouse Investment.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A robotic arm positions a microplate with blue samples above another plate, surrounded by various white laboratory machines in a bright, modern lab setting.

Anew Labs, the AI drug discovery company spun out of ByteDance, has raised a reported $290 million in its first round of external financing, according to sources cited in industry media. The round values the business at $1.5 billion, and was led by three prominent Asian investment firms: HSG, IDG Capital, and Hillhouse Investment. ByteDance is said to retain a 56% controlling stake following the transaction.

No formal press release accompanied the announcement, and neither Anew Labs nor ByteDance had issued a public statement at the time of writing. The funding figures are therefore unconfirmed and carry the caveats typical of pre-announcement or media-sourced reporting.

What Anew Labs does

Anew Labs sits in the rapidly expanding field of AI-assisted drug discovery, which uses large-scale computational models to accelerate target identification, molecule generation, and candidate optimisation. ByteDance's entry into this space reflects a broader pattern of Chinese technology companies leveraging their strengths in large language models and data infrastructure to compete with established players in pharmaceutical research.

The company has not disclosed which therapeutic areas or disease targets it is prioritising, nor has it named a lead programme or announced any academic or pharmaceutical partnerships. Without those details, it is difficult to assess how Anew Labs differentiates itself from the growing field of AI-native drug discovery companies, which includes businesses such as Recursion Pharmaceuticals, Insilico Medicine, and Exscientia, all of which have attracted significant institutional capital and, in some cases, major pharma collaborations.

Market context and competitive positioning

AI drug discovery attracted several billion dollars in aggregate funding globally in 2024 and 2025, and investor appetite remains strong despite a broader biotech funding slowdown. A $1.5 billion valuation at first external funding is notable and places Anew Labs at the upper end of pre-clinical AI drug discovery valuations, reflecting both the scale of ByteDance's proprietary data assets and the competitive premium investors are placing on large-model-native approaches to molecular design.

The involvement of Hillhouse Investment is worth watching. Hillhouse has backed a number of life sciences companies across Asia and has a pattern of anchoring rounds where it sees category-defining potential. IDG Capital similarly has a broad technology portfolio with increasing life sciences exposure.

Regulatory considerations for AI-generated drug candidates remain in flux globally. Both the FDA and EMA have published early guidance on AI use in drug development, but the field is evolving faster than the frameworks. Any future Anew Labs programme heading toward clinical development will need to navigate those uncertainties alongside the standard IND and CTA processes.

The immediate milestones to watch are a named indication, a disclosed platform mechanism, and any early partnership with an established pharmaceutical company that might de-risk the commercial path.

Sector

Topic

Geography